PICH (Plk1-interacting checkpoint helicase), also known by its gene name ERCC6L (Excision Repair Cross-Complementation Group 6-Like), is a DNA helicase that plays a significant role in the cellular processes that maintain genomic stability. Inhibitors targeting PICH_ERCC6L are a class of chemical compounds designed to interact with and impede the normal function of this specific helicase enzyme. By binding to the active or regulatory sites of PICH_ERCC6L, these inhibitors can modulate the enzyme's activity, which is vital for proper chromosome segregation during cell division. PICH_ERCC6L has a unique role in the resolution of DNA structures that pose a challenge to the mitotic machinery, such as ultrafine DNA bridges and catenated DNA strands that can occur during the replication and segregation of genetic material.
The chemical structures of PICH_ERCC6L inhibitors are diverse, reflecting the complexity of the enzyme's structure and the sophisticated mechanisms by which it interacts with DNA. These inhibitors may mimic substrates or cofactors of the helicase, or they may be designed to bind to unique allosteric sites, altering the enzyme's conformation and thereby its activity. By affecting the helicase function, these compounds impact the enzyme's ability to unwind and resolve complex DNA structures, which is a crucial step in the maintenance of chromosomal stability during the cell cycle. The specificity of PICH_ERCC6L inhibitors is particularly important, as it ensures that the compounds do not indiscriminately affect other helicases or DNA-processing enzymes that are critical for normal cell function. The design of these inhibitors often involves an intricate understanding of the molecular dynamics of PICH_ERCC6L, its interaction with binding partners during the cell cycle, and the three-dimensional configuration of its DNA-binding and catalytic sites.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
ATM inhibitors target the ATM kinase, another key player in DNA damage response. Inhibition of ATM can alter the phosphorylation status of proteins involved in the DNA damage response pathway, potentially affecting PICH/ERCC6L's function. | ||||||
PD 153035 | 153436-54-5 | sc-205909 | 5 mg | $146.00 | 5 | |
CHK1 inhibitors disrupt the CHK1 kinase, which plays a critical role in cell cycle checkpoint control. By inhibiting CHK1, these compounds can impact PICH/ERCC6L's role in checkpoint regulation. | ||||||
Tozasertib | 639089-54-6 | sc-358750 sc-358750A | 25 mg 50 mg | $62.00 $87.00 | 4 | |
Aurora kinase inhibitors prevent the activity of Aurora kinases involved in mitotic progression. Disruption of these kinases can affect the mitotic processes where PICH/ERCC6L is active. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
PARP inhibitors block the activity of Poly (ADP-ribose) polymerase enzymes involved in single-strand break repair. By inhibiting PARP, these compounds can create a context of DNA damage that may challenge PICH/ERCC6L function. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitors block the degradation of proteins by the proteasome. This can lead to an accumulation of proteins, including those involved in cell cycle regulation and DNA repair, potentially affecting the cellular environment in which PICH/ERCC6L operates. | ||||||